Evidence map›Paper›PMID 40881684›Full record

ArticleFrontiers in immunology2025

Elevated serum IL-10/IL-6 ratio as a novel biomarker for secondary central nervous system lymphoma and poor prognosis in DLBCL.

Jingjing Wen, Xingyu Nie, Qiaolin Zhou, Yiping Liu, Jing Yue, Ya Zhang, Jing Su, Xiaogong Liang, Fang Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jingjing Wen *Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang, Sichuan, China.
Xingyu Nie *Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang, Sichuan, China.
Qiaolin ZhouDepartment of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang, Sichuan, China.
Yiping LiuDepartment of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang, Sichuan, China.
Jing YueDepartment of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang, Sichuan, China.
Ya ZhangDepartment of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang, Sichuan, China.
Jing SuDepartment of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang, Sichuan, China.
Xiaogong LiangDepartment of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang, Sichuan, China.
Fang XuDepartment of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, National Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma and carries a poor prognosis when it involves the central nervous system (CNS), a condition known as secondary CNS lymphoma (SCNSL). Although the CNS International Prognostic Index (CNS-IPI) is used to estimate SCNSL risk, its limited sensitivity highlights the need for more reliable biomarkers to improve risk stratification and enable earlier intervention. Methods: We evaluated pretreatment levels of interleukin-10 (IL-10) and interleukin-6 (IL-6) in both peripheral blood (PB) and cerebrospinal fluid (CSF), and compared clinical characteristics between DLBCL patients with and without SCNSL. Results: Fifty-six newly diagnosed DLBCL patients who received at least two treatment cycles were included. Compared to patients without CNS relapse, those with SCNSL exhibited distinct clinical features: more frequent B symptoms, increased bone marrow involvement, and lower B-cell lymphoma 6 (BCL6) immunohistochemical positivity. Biochemically, SCNSL patients showed elevated serum IL-10 levels, higher serum IL-10/IL-6 ratios, increased CSF IL-10 concentrations, and markedly elevated CSF IL-10/IL-6 ratios. On multivariate analysis, a serum IL-10/IL-6 ratio ≥2.30 independently predicted both progression-free survival (PFS) (HR = 7.300, Conclusion: In DLBCL, an elevated serum IL-10/IL-6 ratio at diagnosis independently predicts disease progression and SCNSL risk. Incorporating this biomarker enhances the prognostic utility of both CNS-IPI and NCCN-IPI models. Additionally, the markedly elevated CSF IL-10/IL-6 ratio in SCNSL patients suggests potential diagnostic value for CNS involvement, warranting further investigation.

Indexed as

Biomarkers, TumorCentral Nervous System NeoplasmsInterleukin-10Interleukin-6Lymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisYoung AdultBiomarkers, TumorIL10 protein, humanIL6 protein, humanInterleukin-10Interleukin-6central nervous systemdiffuse large B-cell lymphomainterleukin-10interleukin-6prognosis

Identifiers

PMID40881684
PMCPMC12380870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.